HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,867,823 | +38.1% | 310,676 | +30.4% | 0.02% | +36.4% |
| Q2 2023 | $8,593,822 | +113.9% | 238,254 | +126.5% | 0.01% | +83.3% |
| Q1 2023 | $4,017,473 | -66.6% | 105,197 | -50.2% | 0.01% | -66.7% |
| Q4 2022 | $12,023,425 | -99.8% | 211,308 | +37.3% | 0.02% | +80.0% |
| Q3 2022 | $6,085,641,000 | +53.9% | 153,911 | +155.9% | 0.01% | +66.7% |
| Q2 2022 | $3,953,180,000 | +118.4% | 60,145 | +32.5% | 0.01% | +200.0% |
| Q1 2022 | $1,810,193,000 | -75.4% | 45,391 | -18.7% | 0.00% | -80.0% |
| Q4 2021 | $7,352,439,000 | +52.0% | 55,834 | -43.7% | 0.01% | +42.9% |
| Q3 2021 | $4,837,747,000 | +12.7% | 99,122 | +4.9% | 0.01% | +16.7% |
| Q2 2021 | $4,291,790,000 | -7.1% | 94,512 | -14.7% | 0.01% | -14.3% |
| Q1 2021 | $4,620,628,000 | -35.9% | 110,833 | -34.3% | 0.01% | -46.2% |
| Q4 2020 | $7,206,202,000 | +59.0% | 168,724 | -2.1% | 0.01% | +116.7% |
| Q3 2020 | $4,531,171,000 | +9.8% | 172,419 | +12.0% | 0.01% | -14.3% |
| Q2 2020 | $4,128,016,000 | -58.6% | 153,973 | -72.2% | 0.01% | -65.0% |
| Q1 2020 | $9,960,433,000 | +23.0% | 553,665 | +21.2% | 0.02% | +33.3% |
| Q4 2019 | $8,097,876,000 | +1914.5% | 456,733 | +1662.2% | 0.02% | +1400.0% |
| Q3 2019 | $401,988,000 | +39.4% | 25,918 | +54.4% | 0.00% | 0.0% |
| Q2 2019 | $288,315,000 | -38.1% | 16,782 | -42.0% | 0.00% | 0.0% |
| Q1 2019 | $465,837,000 | +15.8% | 28,934 | +5.3% | 0.00% | 0.0% |
| Q4 2018 | $402,106,000 | +35.8% | 27,485 | +68.7% | 0.00% | – |
| Q3 2018 | $296,098,000 | -19.1% | 16,296 | -24.9% | 0.00% | -100.0% |
| Q2 2018 | $366,012,000 | -47.8% | 21,696 | -39.4% | 0.00% | 0.0% |
| Q1 2018 | $701,067,000 | +40.6% | 35,787 | +45.4% | 0.00% | 0.0% |
| Q4 2017 | $498,680,000 | +99.6% | 24,614 | +71.1% | 0.00% | 0.0% |
| Q3 2017 | $249,885,000 | +14.3% | 14,386 | -15.6% | 0.00% | 0.0% |
| Q2 2017 | $218,543,000 | +611.5% | 17,047 | +619.3% | 0.00% | – |
| Q1 2017 | $30,715,000 | -60.3% | 2,370 | -69.7% | 0.00% | – |
| Q4 2016 | $77,390,000 | -29.2% | 7,833 | -13.5% | 0.00% | – |
| Q3 2016 | $109,336,000 | +199.1% | 9,051 | +113.7% | 0.00% | – |
| Q2 2016 | $36,557,000 | -90.5% | 4,236 | -80.8% | 0.00% | -100.0% |
| Q4 2015 | $383,096,000 | -23.6% | 22,106 | -40.8% | 0.00% | 0.0% |
| Q3 2015 | $501,570,000 | +36.1% | 37,347 | +128.8% | 0.00% | 0.0% |
| Q2 2015 | $368,596,000 | +158.8% | 16,324 | +63.7% | 0.00% | – |
| Q1 2015 | $142,400,000 | +145.5% | 9,972 | +56.4% | 0.00% | – |
| Q3 2014 | $58,003,000 | -80.4% | 6,374 | -78.7% | 0.00% | – |
| Q2 2014 | $295,827,000 | +1613.1% | 29,942 | +2499.1% | 0.00% | – |
| Q4 2013 | $17,269,000 | -93.5% | 1,152 | -95.2% | 0.00% | – |
| Q3 2013 | $267,521,000 | +10.6% | 24,232 | -20.3% | 0.00% | – |
| Q2 2013 | $241,815,000 | – | 30,417 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |